Clinical and Molecular Characterization of Surgically Treated Oropharynx Squamous Cell Carcinoma Samples

  • Ana Carolina de CarvalhoEmail author
  • Matias Eliseo Melendez
  • Cristina da Silva Sabato
  • Edenir Inez Palmero
  • Lidia Maria Rebolho Batista Arantes
  • Cristovam Scapulatempo Neto
  • André Lopes Carvalho
Original Article


A better understanding of the clinical and molecular features of oropharyngeal squamous cell carcinomas (OPSCC) may help in the development of strategies for a better patient management, improving survival rates. This retrospective study conducted a clinical and molecular characterization of surgically treated OPSCC samples. Paraffin-embedded samples from a series of cases were screened for high-risk (HR) human papillomavirus (HPV) infection, methylation of a 5-gene panel, p53 expression, and TP53 mutation. The study was conducted at Barretos Cancer Hospital. Twenty-five surgically treated OPSCC with available tissue were included in the study. Samples were classified according to HPV status and molecular features and some of these characteristics were associated to clinical data. Twenty percent of the cases were HR-HPV positive and 62.5% presented TP53 mutations. DAPK hypermethylation was associated with HPV status (p = 0.023), while methylated CCNA1 was inversely related to TP53 mutations in primary tumors (p = 0.042) and associated with a better disease-free survival (22.3% vs. 100.0%; p = 0.028) and overall survival (8.0% vs. 100.0%; p = 0.012). The results show differences regarding molecular and clinical characteristics in the oropharynx cases identified that should be validated in more cases to confirm whether these differences are able to classify patients according to outcome and help in a more thorough patient management.


Oropharyngeal cancer Human papillomavirus Methylation Mutation Prognosis 



This study was funded by São Paulo Research Foundation (FAPESP), grant # 2015/01286-0 and National Counsel of Technological and Scientific Development (CNPq), grant # 445.053/2014-3. ACC was recipient of scholarship from São Paulo Research Foundation (FAPESP). ALC has a National Counsel of Technological and Scientific Development (CNPq) scholarship.

Supplementary material

12253_2018_462_MOESM1_ESM.doc (34 kb)
Appendix 1 Primers and probes used in the QMSP assays. (DOC 34 kb)
12253_2018_462_MOESM2_ESM.docx (16 kb)
Appendix 2 Description of the clinical and molecular data of the 25 OPSCC patients enrolled in the study. (DOCX 16.3 kb)


  1. 1.
    Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407–420. CrossRefPubMedGoogle Scholar
  2. 2.
    Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11(8):781–789. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Marklund L, Hammarstedt L (2011) Impact of HPV in oropharyngeal Cancer. J Oncol 2011:509036. CrossRefPubMedGoogle Scholar
  4. 4.
    Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C (2015) Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 33(29):3235–3242. CrossRefGoogle Scholar
  5. 5.
    Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14(2):467–475. CrossRefPubMedGoogle Scholar
  6. 6.
    Zhen W, Karnell LH, Hoffman HT, Funk GF, Buatti JM, Menck HR (2004) The National Cancer Data Base report on squamous cell carcinoma of the base of tongue. Head Neck 26(8):660–674. CrossRefPubMedGoogle Scholar
  7. 7.
    Lybak S, Ljokjel B, Haave H, Karlsdottir A, Vintermyr OK, Aarstad HJ (2017) Primary surgery results in no survival benefit compared to primary radiation for oropharyngeal cancer patients stratified by high-risk human papilloma virus status. Eur Arch Otorhinolaryngol 274(1):477–487. CrossRefPubMedGoogle Scholar
  8. 8.
    Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol Off J Am Soc Clin Oncol 29(32):4294–4301. CrossRefGoogle Scholar
  9. 9.
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92(9):709–720CrossRefPubMedGoogle Scholar
  10. 10.
    Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E (2000) Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89(3):300–304CrossRefPubMedGoogle Scholar
  11. 11.
    Hafkamp HC, Manni JJ, Haesevoets A, Voogd AC, Schepers M, Bot FJ, Hopman AH, Ramaekers FC, Speel EJ (2008) Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 122(12):2656–2664. CrossRefPubMedGoogle Scholar
  12. 12.
    Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI, Califano JA, Tufano RP, Koch WM (2008) Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 30(7):898–903. CrossRefPubMedGoogle Scholar
  13. 13.
    Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK (2012) Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol Off J Am Soc Clin Oncol 30(17):2102–2111. CrossRefGoogle Scholar
  15. 15.
    Deschler DG, Richmon JD, Khariwala SS, Ferris RL, Wang MB (2014) The “new” head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg 151(3):375–380. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Dansky Ullmann C, Harlan LC, Shavers VL, Stevens JL (2012) A population-based study of therapy and survival for patients with head and neck cancer treated in the community. Cancer 118(18):4452–4461. CrossRefPubMedGoogle Scholar
  17. 17.
    Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, Ringash J, Bayley A, Kim J, Hope A, Cho J, Giuliani M, Hansen A, Irish J, Gilbert R, Gullane P, Perez-Ordonez B, Weinreb I, Liu FF, O'Sullivan B (2015) Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 33(8):836–845. CrossRefPubMedGoogle Scholar
  18. 18.
    Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM (2001) Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92(4):805–813CrossRefPubMedGoogle Scholar
  19. 19.
    Dahlstrand HM, Dalianis T (2005) Presence and influence of human papillomaviruses (HPV) in tonsillar cancer. Adv Cancer Res 93:59–89. CrossRefPubMedGoogle Scholar
  20. 20.
    Shimura E, Hama T, Suda T, Ikegami M, Urashima M, Kojima H (2017) The presence of HPV DNA in neck lymph node metastasis correlates with improved overall survival of patients with oropharyngeal cancer undergoing surgical treatment. Oncology 92(2):87–93. CrossRefPubMedGoogle Scholar
  21. 21.
    Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A (2006) Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol Off J Am Soc Clin Oncol 24(5):736–747. CrossRefGoogle Scholar
  22. 22.
    Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9(17):6469–6475PubMedGoogle Scholar
  23. 23.
    Singhi AD, Westra WH (2010) Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 116(9):2166–2173. PubMedCrossRefGoogle Scholar
  24. 24.
    Keswani RN, Noffsinger A, Waxman I, Bissonnette M (2006) Clinical use of p53 in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 15(7):1243–1249. CrossRefPubMedGoogle Scholar
  25. 25.
    Rettori MM, de Carvalho AC, Bomfim Longo AL, de Oliveira CZ, Kowalski LP, Carvalho AL, Vettore AL (2013) Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients. Carcinogenesis 34(1):20–27. CrossRefPubMedGoogle Scholar
  26. 26.
    Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, Holscher AH, Meltzer SJ, Danenberg PV (2001) Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20(27):3528–3532. CrossRefPubMedGoogle Scholar
  27. 27.
    Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol Off J Am Soc Clin Oncol 31(36):4550–4559. CrossRefGoogle Scholar
  28. 28.
    Howard J, Masterson L, Dwivedi RC, Riffat F, Benson R, Jefferies S, Jani P, Tysome JR, Nutting C (2016) Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane Database Syst Rev 12:CD010963. PubMedCrossRefGoogle Scholar
  29. 29.
    Parsons JT, Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Villaret DB, Moore-Higgs GJ, Greene BD, Speer TW, Cassisi NJ, Million RR (2002) Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 94(11):2967–2980. CrossRefPubMedGoogle Scholar
  30. 30.
    Blanchard P, Hill C, Guihenneuc-Jouyaux C, Baey C, Bourhis J, Pignon JP (2011) Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 64(9):985–992. CrossRefPubMedGoogle Scholar
  31. 31.
    Lee J, Chang JS, Kwon HJ, Kim SH, Shin SJ, Keum KC (2016) Impact of p16 expression in oropharyngeal cancer in the postoperative setting: the necessity of re-evaluating traditional risk stratification. Jpn J Clin Oncol 46(10):911–918. CrossRefPubMedGoogle Scholar
  32. 32.
    Dahlstrom KR, Calzada G, Hanby JD, Garden AS, Glisson BS, Li G, Roberts DB, Weber RS, Sturgis EM (2013) An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer 119(1):81–89. CrossRefPubMedGoogle Scholar
  33. 33.
    D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356(19):1944–1956. CrossRefPubMedGoogle Scholar
  34. 34.
    O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W (2013) Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol Off J Am Soc Clin Oncol 31(5):543–550. CrossRefGoogle Scholar
  35. 35.
    Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM, McArthur GA (2010) Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 28(27):4142–4148. CrossRefGoogle Scholar
  36. 36.
    Huang SH, Perez-Ordonez B, Weinreb I, Hope A, Massey C, Waldron JN, Kim J, Bayley AJ, Cummings B, Cho BC, Ringash J, Dawson LA, Siu LL, Chen E, Irish J, Gullane P, Hui A, Liu FF, Shen X, Xu W, O'Sullivan B (2013) Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 49(1):79–85. CrossRefPubMedGoogle Scholar
  37. 37.
    McIlwain WR, Sood AJ, Nguyen SA, Day TA (2014) Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 140(5):441–447. CrossRefPubMedGoogle Scholar
  38. 38.
    Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3(7):761–769. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333(6046):1157–1160. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ (2013) Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3(7):770–781. CrossRefPubMedGoogle Scholar
  41. 41.
    Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154–1157. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Mountzios G, Rampias T, Psyrri A (2014) The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Ann Oncol 25(10):1889–1900. CrossRefPubMedGoogle Scholar
  43. 43.
    Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517 (7536):576–582.
  44. 44.
    Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL (2007) Clinical implications and utility of field cancerization. Cancer Cell Int 7:2. CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22. CrossRefPubMedGoogle Scholar
  46. 46.
    Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357(25):2552–2561. CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    van Houten VM, Tabor MP, van den Brekel MW, Kummer JA, Denkers F, Dijkstra J, Leemans R, van der Waal I, Snow GB, Brakenhoff RH (2002) Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 198(4):476–486. CrossRefPubMedGoogle Scholar
  48. 48.
    Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63(6):1188–1191PubMedGoogle Scholar
  49. 49.
    Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG, Goberdhan A, Shah JP, Singh B (2003) High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 129(1):106–112CrossRefPubMedGoogle Scholar
  50. 50.
    Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price P, Waldron J, Goldstein D, Meyer F, Bairati I, Liu G (2008) Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 17(3):490–499. CrossRefPubMedGoogle Scholar
  51. 51.
    Smith RB, Sniezek JC, Weed DT, Wax MK (2007) Utilization of free tissue transfer in head and neck surgery. Otolaryngol Head Neck Surg 137(2):182–191. CrossRefPubMedGoogle Scholar
  52. 52.
    Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, Yoo GH, Lee DJ, Forastiere AA, Sidransky D (1996) p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 88(21):1580–1586CrossRefPubMedGoogle Scholar
  53. 53.
    Graveland AP, Golusinski PJ, Buijze M, Douma R, Sons N, Kuik DJ, Bloemena E, Leemans CR, Brakenhoff RH, Braakhuis BJ (2011) Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int J Cancer 128(8):1852–1859. CrossRefPubMedGoogle Scholar
  54. 54.
    Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25(7):1070–1080. CrossRefPubMedGoogle Scholar
  55. 55.
    Don KR, Ramani P, Ramshankar V, Sherlin HJ, Premkumar P, Natesan A (2014) Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: a systematic review and meta-analysis. Indian J Dent Res 25(6):797–805. CrossRefPubMedGoogle Scholar
  56. 56.
    Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60(4):892–895PubMedGoogle Scholar
  57. 57.
    Noorlag R, van Kempen PM, Moelans CB, de Jong R, Blok LE, Koole R, Grolman W, van Diest PJ, van Es RJ, Willems SM (2014) Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer. Epigenetics 9(9):1220–1227. CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    van Kempen PM, Noorlag R, Braunius WW, Stegeman I, Willems SM, Grolman W (2014) Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 9(2):194–203. CrossRefPubMedGoogle Scholar
  59. 59.
    Sartor MA, Dolinoy DC, Jones TR, Colacino JA, Prince ME, Carey TE, Rozek LS (2011) Genome-wide methylation and expression differences in HPV(+) and HPV(−) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 6(6):777–787CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Choudhury JH, Ghosh SK (2015) Promoter hypermethylation profiling identifies subtypes of head and neck cancer with distinct viral, environmental, genetic and survival characteristics. PLoS One 10(6):e0129808. CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, Seiwert T, Dyckhoff G, Dietz A, Hofler D, Pawlita M, Benner A, Bosch FX, Plinkert P, Plass C, Weichenhan D, Hess J (2013) HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest 123(6):2488–2501. CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, Hoque MO, Westra WH, Califano JA, Sidransky D (2004) Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 64(17):5982–5987. CrossRefPubMedGoogle Scholar
  63. 63.
    Perdomo S, Martin Roa G, Brennan P, Forman D, Sierra MS (2016) Head and neck cancer burden and preventive measures in Central and South America. Cancer Epidemiol 44(Suppl 1):S43–S52. CrossRefPubMedGoogle Scholar
  64. 64.
    Lopez CR, Antoni MH, Pereira D, Seay J, Whitehead N, Potter J, O'Sullivan M, Fletcher MA (2013) Stress management, depression and immune status in lower income racial/ethnic minority women co-infected with HIV and HPV. J Appl Biobehav Res 18(1):37–57. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  • Ana Carolina de Carvalho
    • 1
    Email author
  • Matias Eliseo Melendez
    • 1
  • Cristina da Silva Sabato
    • 3
  • Edenir Inez Palmero
    • 1
    • 3
  • Lidia Maria Rebolho Batista Arantes
    • 1
  • Cristovam Scapulatempo Neto
    • 1
    • 4
  • André Lopes Carvalho
    • 1
    • 2
  1. 1.Molecular Oncology Research CenterBarretos Cancer HospitalBarretosBrazil
  2. 2.Department of Head and Neck SurgeryBarretos Cancer HospitalBarretosBrazil
  3. 3.Center of Molecular DiagnosisBarretosBrazil
  4. 4.Department of PathologyBarretos Cancer HospitalBarretosBrazil

Personalised recommendations